Document:

EX-10.9 Conditionally Exclusive License Agreement

 

EXHIBIT 10.9

February 7, 2000

Dr. Peter Law

Cell Transplants International, LLC

2015 Miller Farms Road

Germantown, TN 38138

REF: License Agreement

Dear Dr. Law,

This letter serves as a full license agreement covering all patents and patents pending and
also future developments related to heart muscle function improvement and angiogenesis. Please
sign and return this today by fax so we may proceed to send you the initial license fee payment of
$500,000, as discussed.

	1.	 	We seek to license all patents related to myogenic cell transplantation and
controlled cell fusion as may be necessary to develop a commercially viable product
within the field of “heart muscle repair and angiogenesis”.
	 
	2.	 	CTI/CTAL will grant Bioheart, Inc. a NON-EXCLUSIVE license for all patents
related to heart muscle regeneration and angiogenesis for the life of the patents.
Sublicensing of these patents by Bioheart, Inc. is not allowed.
	 
	3.	 	Bioheart agrees to provide $500,000 in research funding to CTI/CTAL within 90
days of the signing of this letter of intent to further research mutual interest.
	 
	4.	 	Bioheart will provide immediately to CTI/CTAL or Dr. Peter Law 600,000 shares
of Bioheart common stock at $1.80 per share as part of the license fee payment.
	 
	5.	 	Bioheart will provide CTI/CTAL or Dr. Peter Law, in 30 days, option to acquire
another 600,000 shares of Bioheart common stock at $1.80 per share.
	 
	6.	 	Bioheart, Inc. will pay a royalty of 5% of gross sales of products and services
that directly read upon the claims of the patents.
	 
	7.	 	Bioheart, Inc. will provide agreement which states that dilution of shares of
CTI/CTAL or Dr. Peter Law will at all times be equal to dilution of Mr. Howard
Leonhardt and the family and friends of Mr. Leonhardt.
	 
	8.	 	Dr. Peter Law will be elected to the Board of Directors of Bioheart, Inc.

 

 

	9.	 	CTI/CTAL will be responsible for pursuing and suing infringers of Dr. Law’s
patents and will thus be entitled to 100% of any damages paid in.
	 
	10.	 	Bioheart agrees to enter into a supply agreement with CTI/CTAL for cultured
myoblasts in 30 days.
	 
	11.	 	Bioheart, Inc. will pay $3,000,000 to CTI/CTAL upon INITIATION of a human
clinical trial study of Dr. Law’s patented technology with F.D.A. approval in the
United States (does not include isolated compassionate use or emergency last resort
cases which are not part of the study).
	 
	12.	 	Bioheart, Inc. will pay $5,000,000 to CTI/CTAL upon F.D.A. APPROVAL of method
of heart muscle regeneration utilizing the patented technology.
	 
	13.	 	Right of first refusal — If Dr. Law/CTAL receives a bona fide offer from a
direct competitor of Bioheart’s in heart muscle repair, Bioheart shall have 30 days to
meet this offer to bar competition from obtaining license. Bioheart will have
permission to express this covenant of the agreement to investors as a “semi-exclusive
license”.

Kindest Regards,

	 	 	 
	Howard J. Leonhardt
	 	 
	 

	 	 
	Chairman & CEO

	 	Dr. Peter Law, Chairman & CEO
	 

	 	Cell Transplants International, LLC

2

 

Dr. Peter Law

Cell Transplants International, LLC

2015 Miller Farms Road

Germantown, TN 38138

REF: License Agreement

Dear Dr. Law:

This letter (“Addendum”) amends and supplements that certain full license agreement (“Agreement”)
covering all patents and patents pending and future developments related to heart muscle function
regeneration and Angiogenesis dated February 7, 2000 between Bioheart, Inc. (“Bioheart” or the
“Company”), Dr. Peter Law and Cell Transplants International, LLC (“CTI”). Except as noted below,
the provisions of the Agreement remain in full force and effect. This Addendum shall be deemed
effective as of February 7, 2000.

	1.	 	Dr. Law and CTI shall each execute and deliver to Bioheart the following
agreements concurrently with their execution and delivery of this letter agreement:

	 	(a)	 	a Scientific Advisory Board Consultation Agreement in the form
attached hereto as Exhibit A;
	 
	 	(b)	 	a Supply Agreement in the form attached hereto as Exhibit B;
	 
	 	(c)	 	an Inventions and Proprietary Rights Assignment and
Confidentiality Agreement in the form attached hereto as Exhibit D; and
	 
	 	(d)	 	a Warrant Certificate in the form attached hereto as Exhibit E
(the “Warrant”).

It shall be an express condition precedent to the effectiveness of this Addendum
that each of the above-identified agreements be executed and delivered by the
parties hereto. This Section 1 supersedes Section 10 of the Agreement.

	2.	 	In consideration of Dr. Law’s and CTI’s execution, delivery and performance of
the above-identified agreements as well as the Agreement, as amended and supplemented
hereby, Bioheart, Dr. Law and CTI agree as follows:

	 	(a)	 	the aggregate license/research and development fees payable by
Bioheart under this first paragraph and Section 3 of the Agreement is a total
sum of

 

 

	 	 	 	$1,000,000, of which Dr. Law and CTI acknowledge that $500,000 of this fee
has been paid previously by Bioheart as noted in the first paragraph of the
Agreement. The $500,000 balance of said fees shall be paid upon execution
of this contract. In addition to the obligations under Section 9 of the
Agreement, Dr. Law and CTI shall undertake reasonably diligent and prompt
efforts to enforce said patents by instituting litigation against all third
parties, whether now known or identified in the future with respect to whom
Dr. Law and/or CTI have a reasonable basis for claiming infringement.
Additionally, Dr. Law and/or CTI will continue to provide Bioheart with all
pertinent and critical information in order to file an IND with the FDA and
to have it approved by the FDA. Dr. Law and/or CTI will agree to allow
Bioheart Quality Assurance expert complete access to the CTI facilities in
order for them to (i) assist CTI in compiling adequate QC documentation and
(ii) ensure that CTI will be able to provide Bioheart with FDA QC validated
cells. Additionally, Dr. Law and/or CTI will agree to provide a license, in
reasonable form, to Duke University to continue Bioheart research. This
Section 2(a) supercedes Section 3 of the Agreement in its entirety; and
	 
	 	(b)	 	Bioheart will issue to CTI a 5-year warrant exercisable for
1,200,000 shares of Bioheart common stock at an exercise price of $8.00 per
share, pursuant to the terms of the Warrant, instead of the 600,000 shares and
600,000 options referenced in Sections 4 and 5 of the Agreement. This Section
2(b) supersedes Sections 4 and 5 of the Agreement in their entirety; and
	 
	 	(c)	 	Bioheart will pay $3,000,000 to CTI upon commencement of a bona
fide Phase II human clinical trial study that utilizes technology claimed under
U.S. Patent No. 5,130,141 with F.D.A. approval in the United States (it being
understood that such a study does not include isolated compassionate use or
emergency last resort cases which are not part of study). This Section 2(c)
supersedes Section 11 of the Agreement.

	3.	 	Additionally, if Dr. Law or CTI desires to license or otherwise convey any
rights in and to any of their technology, inventions or patent rights to a third party
in the field of heart muscle regeneration or Angionesis efforts (whether in response to
a bona fide other from such third party or otherwise), Bioheart shall have a right of
first refusal over any such third party to obtain either exclusive or non-exclusive
license and acquire such rights Dr. Law and CTI shall provide written notice to
Bioheart regarding such proposed transaction, terms and, if such proposed transaction
is in response to a bona fide third party offer, the terms of such offer. Bioheart
shall have the first right to complete the proposed transaction with Dr. Law and/or CTI
on the proposed terms by providing written notice to Dr. Law and/or CTI, as the case
may be, of its acceptance of such proposed terms, which

2

 

	 	 	notice shall be provided no later than thirty (30) days after Bioheart’s receipt of
notice regarding such proposed transaction. Bioheart’s failure to provide such
acceptance notice to Dr. Law and/or CTI, as the case may be, within such thirty (30)
day period shall be deemed to constitute rejection of such offer, in which event Dr.
Law and/or CTI shall be entitled to proceed with its/their proposed transaction with
such third party; provided, however, that if the terms of such transaction are
modified or a new offer is made, or if the transaction does not occur within 30
days, the Company shall be entitled to again receive a new notice and a right of
first refusal pursuant to the provisions set forth above with regard to such
modified terms or new offer. It shall be an express condition precedent to
completion of any transaction with a third party that such third party acknowledge
Bioheart’s license rights in and to such technology, and if such transaction
involves the assignment of patent rights by Dr. Law and/or CTI to such third party,
that such third party assume all obligations of Dr. Law and/or CTI as licensor with
respect to Bioheart’s rights in and to the technology being transferred. The
parties hereto acknowledge and agree that Dr. Law and CTI shall not in any event
consider or accept any such third party offers or otherwise enter into or consummate
any such transaction wherein the aggregate consideration payable is less than
$14,000,000. The parties hereto further acknowledge that the value of the
consideration required to be paid by Bioheart, Inc. in connection with an offer to
license any of Dr. Law and/or CTI’s technology, inventions or patent rights to a
third party in the field of heart muscle regeneration and/or Angiogenesis,
exercising its right of first refusal hereunder (whether paid in cash or in the form
of equity securities) shall be equal to the lesser of the bona fide terms offered to
or by such third party or $25,000,000, and in any event Bioheart shall only be
required to pay the cash portion and the common stock traded on an internationally
recognized stock exchange of the consideration that would be paid by such third
party in such proposed transaction. Bioheart will have permission to express this
covenant of the agreement to investors as a “conditionally exclusive license.” This
Section 3 supersedes Section 13 of the Agreement.

[The remainder of this page intentionally left blank; signatures on following page.]

3

 

If the foregoing terms are acceptable to you, please acknowledge your acceptance and agreement by
executing both enclosed originals of this letter agreement and returning one executed original to
my attention.

Kindest Regards,

BIOHEART, INC.

 

John L. Babitt

Chief Financial Officer

Accepted by:

__________________________

Dr. Peter K. Law, Ph.D., individually

CELL TRANSPLANTS INTERNATIONAL LLC

__________________________

By: Dr. Peter K. Law, PhD., Chairman and Executive Officer

4

 

January 18, 2001

VIA FACSIMILE

Mr. John Babitt

Bioheart, Inc.

2400 North Commerce Parkway

Suite 408

Weston, FL 33326

Dear John:

This letter will confirm our previous telephone conversation wherein we discussed Peter Law’s
decision to decline membership on the Board of Directors of Bioheart, Inc. due to potential
conflicts of interest which might arise. You acknowledged the potential conflicts of interest and
agreed that the parties’ relationship more appropriately proceeds without a board position for Dr.
Law. This letter will specifically reference the February 7, 2000 letter agreement between the
parties and confirm that Bioheart, Inc. has satisfied its obligation to offer a board seat to Peter
Law and that Peter Law remains in compliance with that letter agreement despite his declining the
board seat.

If you have any questions in this regard, please feel free to call me. Thanks.

Sincerely,

Anthony C. Pierrangelo

ACP/mbh

cc: Dr. Peter LawEX-10.11 Loan Guarantee

 

EXHIBIT 10.11

EXECUTION COPY

Loan Agreement No:                                         

Guarantor Name:       HOWARD AND BRENDA LEONHARDT

Guarantee Amount:     $1,100,000.00

LOAN GUARANTEE, PAYMENT AND SECURITY AGREEMENT

     This Agreement (the “Agreement”) is made as of June 1, 2007 (the “Effective
Date”), by and between BIOHEART, INC., a Florida corporation (the “Company”), and
Howard and Brenda Leonhardt (the “Guarantor”).

WITNESSETH:

     WHEREAS, the Company expects to obtain a term loan (the “Loan”), in the principal
amount of $5,000,000, from Bank of America, N.A. (the “Bank”);

     WHEREAS, as a condition precedent to the Bank’s making the Loan and as security for the
Company’s obligations relating thereto, the Guarantor will (i) pledge and assign to the Bank (the
“Pledge”) and grant to the Bank a first-priority security interest in, a investment
management account with the Bank having assets of at least $1,100,000 in value deposited in such
account (the “Collateral Account”) and/or (ii) execute and deliver a guaranty agreement
(the “Personal Guaranty”) in favor of the Bank with a maximum liability to the bank of
$1,100,000;

     WHEREAS, subject to the closing of the Loan and in accordance with the terms of this
Agreement, the Guarantor has agreed to make payments to the Company equal to 20% (the
“Guaranteed Percentage”) of the interest and principal payable by the Company to the Bank
in connection with the Loan, which amounts shall be used by the Company solely to pay interest and
principal on the Loan;

     WHEREAS, as consideration for the Guarantor’s agreement to make the payments described above
and to grant, in favor of the Bank, the Pledge and/or the Personal Guaranty, the Company has
agreed, upon the terms and conditions set forth herein, to (i) issue the Guarantor a warrant or
warrants to purchase shares of the Company’s common stock, par value $.001 per share (the
“Common Stock”), and (ii) pay certain fees to the Guarantor;

     NOW, THEREFORE, in consideration of the foregoing premises and other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged by the parties hereto,
the Company and the Guarantor agree as follows:

1. CONSIDERATION.

     1.1 GUARANTEE DOCUMENTS AND PAYMENTS FOR THE BENEFIT OF THE COMPANY.

     In consideration of the Company’s issuance of the Warrant (as defined in Section 1.2 below)
and payment of the Guarantee Fee (as defined in Section 1.2 below), the Guarantor hereby agrees
that it shall:

1

 

EXECUTION COPY

          (a) At Closing (as defined in Section 2.1 below), execute and deliver, in favor of the Bank,
whatever documentation (such documentation, the “Guarantee Documents”) the Bank reasonably
requires in connection with the Personal Guaranty and/or the Pledge.

          (b) During the period commencing on the Effective Date and terminating on the date that the
Company’s payment obligations under the Loan are satisfied and/or discharged in full, at least ten
(10) business days prior to the due date for any payment of interest (“Interest Payment”)
or payment of principal (“Principal Payment”) or other payment required to be made by the
Company to the Bank under the Loan, pay the Company or the Bank an amount equal to the product
obtained by multiplying (x) the total amount of the payment then due and (y) the Guaranteed
Percentage (each such payment, a “Guarantor Payment”) provided, that the aggregate
amount of Guarantor Payments shall not exceed $1,100,000. The Guarantor may, at its option, elect
to make Guarantor Payments by drawing, or authorizing the Bank to draw, on the Collateral Account,
if approved by the Bank. The Company shall apply the Guarantor Payment towards an Interest
Payment, Principal Payment or other payment due in connection with the Loan, and shall either
notify the Guarantor in writing of the due date for any such payment, or shall promptly forward to
the Guarantor any correspondence received by the Company from the Bank regarding the amount and due
date of such Interest Payment, Principal Payment or other payment (as applicable). All payments
hereunder shall be made to a specified account of the Company maintained at the Bank.

          (c) The Guarantor hereby authorizes the Company to notify the Bank in the event that the
Guarantor fails to make a Guarantor Payment when due.

     1.2 ISSUANCE OF WARRANTS AND PAYMENT OF MONTHLY FEES

     In consideration of the Guarantor’s issuing the Personal Guaranty and/or the Pledge in favor
of the Bank the Company hereby agrees that it shall:

          (a) At Closing (as defined in Section 2.1 below), issue to the Guarantor a warrant to purchase
an aggregate of 57,860 shares (the “Subject Shares”) of the Common Stock, with an exercise price of
$4.75 per share, in the form attached hereto as Exhibit A (the “Warrant”). The
Warrant will provide that the number of Subject Shares will increase to 66,000 shares of the Common
Stock in the event the Company has not satisfied and/or discharged all of its payment obligations
under the Loan by September 30, 2007 (the “Loan Satisfaction”). The Warrant will further
provide that the number of Subject Shares will increase to 82,500, 110,000 and 165,000,
respectively, in the event the Company has not satisfied and/or discharged all of its payment
obligations under this Agreement and the Loan by the first anniversary, second anniversary and
third anniversary of the Effective Date, respectively.

          (b) Pay the Guarantor a cash fee (the “Guarantee Fee”) in the amount determined by
multiplying $1,100,000 by 5.0% and multiplying the resulting amount by a fraction, the numerator of
which is the number of days elapsed between the date hereof and the earlier of (i) the date of the
Loan Satisfaction and (ii) the date that is eight months following the Effective Date (or such
later date to which the maturity date of the Note may be extended), and the denominator of which is
365 in accordance with the terms of this Section 1.2(b). The Company shall pay the Guarantee Fee
within five (5) business days of the Trigger Date (as defined below). For purposes of this
Agreement, the “Trigger Date” shall mean the earliest to occur of: (i) the closing date of
an initial public offering of the Company’s Common Stock generating at least $30 million of net
proceeds to the Company occurring on or before January 31, 2008 (a “Qualified Offering”),
and (ii) the date the Company satisfies and/or discharges all of its payment obligations (a
“BlueCrest Loan Satisfaction”) under that certain Loan and Security Agreement, dated as of
May 31, 2007 by and between the Company and BlueCrest Capital Finance, L.P. (the “BlueCrest
Loan”).

2

 

EXECUTION COPY

          (c) If on or before the first business day of the 36th full calendar month after
the date of the BlueCrest Loan (the “Outside Payment Date”), the Company has not
effectuated a BlueCrest Loan Satisfaction or a Qualified Offering:

               (A) the Company shall use its best efforts to effectuate a BlueCrest Loan Satisfaction as soon
as possible following the Outside Payment Date; and

               (B) the Company shall pay the Guarantee Fee no later than five (5) business days following a
BlueCrest Loan Satisfaction.

2. THE CLOSING.

     2.1. CLOSING DATE. The parties agree to effect the transactions contemplated hereby (the
“Closing”) contemporaneously with the execution of this Agreement, which Closing shall be
contemporaneous with the closing of the Loan.

     2.2 CLOSING DELIVERABLES.

          (a) At the Closing, the Company shall deliver or cause to be delivered to the Guarantor:

               (i) an executed copy of this Agreement; and

               (ii) an executed copy of the Warrant.

          (b) At the Closing, the Guarantor shall deliver or cause to be delivered to the Company an
executed copy of this Agreement.

          (c) At the Closing, the Guarantor shall deliver to the Bank duly executed copies of the
Guarantee Documents.

3. RESTRICTIONS ON TRANSFER OF THE WARRANT

     No transfer of all or any portion of the Warrant shall be made except in accordance with the
applicable provisions of this Agreement and/or the Warrant.

4. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY.

     The Company hereby represents, warrants and covenants to the Guarantor and agrees as set forth
below; provided, however, that the Guarantor shall not be able to rely on any representation and/or
warranty made by the Company if Mr. Leonhardt, who is the Executive Chairman and Chief Technology
Officer of the Company, has actual knowledge as of the Effective Date that such representation is
inaccurate:

     4.1. CORPORATE POWER. The Company is a corporation duly organized, validly existing, and in
good standing under the laws of the State of Florida and is duly qualified to do business as a
foreign corporation and is in good standing in each jurisdiction in which the failure to so qualify
would have a material adverse effect on the Company’s business, properties, or financial condition
(a “Material Adverse Effect”). The Company has all requisite corporate power and authority
to execute and deliver this Agreement, the Warrant and the agreements related to the Loan and to
carry out and perform

3

 

EXECUTION COPY

its obligations hereunder and thereunder. The Company has all requisite corporate power and
authority to issue and deliver the shares of Common Stock issuable upon valid exercise of the
Warrant.

     4.2 AUTHORIZATION. This Agreement has been duly authorized, executed and delivered by the
Company. All corporate action on the part of the Company and its shareholders, directors and
officers necessary for the authorization, execution and delivery of this Agreement, the execution
of the agreements related to the Loan, the issuance of the Warrant and the shares of Common Stock
issuable upon conversion of the Warrant, the consummation of the other transactions contemplated
hereby and the performance of all the Company’s obligations hereunder has been taken. This
Agreement constitutes the legal, valid and binding obligation of the Company, enforceable against
the Company in accordance with its terms, subject to (i) laws of general application relating to
bankruptcy, insolvency and the relief of debtors, (ii) rules of law governing specific performance,
injunctive relief and other equitable remedies, and (iii) the limitations imposed by applicable
federal or state securities laws on the indemnification provisions contained in this Agreement. The
shares of Common Stock issuable upon exercise of the Warrant have been duly authorized (the
“Warrant Shares”). When the Warrant Shares have been delivered against payment in
accordance with the terms of the Warrant, such Conversion Shares will have been, validly issued,
fully paid and nonassessable.

     4.3. GOVERNMENTAL CONSENTS. All consents, approvals, orders, or authorizations of, or
registrations, qualifications, designations, declarations, or filings with, any governmental
authority, required on the part of the Company in connection with the valid execution and delivery
of this Agreement, the offer, sale and issuance of the Warrant have been obtained and will be
effective at the Closing, except for notices required or permitted to be filed thereafter with
certain state and federal securities commissions, which notices shall be filed on a timely basis.

     4.4. OFFERING. Assuming the accuracy of the representations and warranties of the Guarantor
contained in Section 5 below, the offer, sale and issuance of the Warrant is exempt from the
registration and prospectus delivery requirements of the Securities Act and has been registered or
qualified (or is exempt from registration and qualification) under the registration, permit, or
qualification requirements of all applicable state securities laws.

     4.5. CAPITALIZATION. The authorized capital of the Company consists of 40,000,000 shares of
Common Stock and 5,000,000 shares of Preferred Stock. As of March 31, 2007, 20,948,994 shares of
Common Stock and no shares of Preferred Stock were issued and outstanding.

     4.5 USE OF PROCEEDS FROM GUARANTOR CASH PAYMENTS. The Company shall use the proceeds of any
Guarantor Payment solely to pay amounts due or payable under the Loan.

     4.6 LITIGATION. Except as referenced on Exhibit 3(d) to the Loan Agreement, there is no
proceeding involving the Company pending or, to the knowledge of the Company, threatened before
any court or governmental authority, agency or arbitration authority.

     4.7 NO CONFLICTING AGREEMENTS. There is no charter, bylaw, stock provision, partnership
agreement or other document pertaining to the organization, power or authority of the Company and
no provision of any existing agreement (including, without limitation, the Loan Agreement with
Bank of America (the “Loan Agreement”) or the Senior Loan Agreement [as defined in the
Loan Agreement]), mortgage, indenture or contract binding on the Company or affecting its
property, which would conflict with or in any way prevent the execution, delivery or carrying out
of the terms of this Agreement.

     4.8 OWNERSHIP OF ASSETS. The Company has good title to its assets, and its assets

4

 

EXECUTION COPY

are free and clear of liens, except for the security interest of BlueCrest (as defined in the
Loan Agreement). For purposes of this Section 4.8, a sublicense of any of the Company’s
intellectual property is not deemed to be a “lien”.

     4.9 TAXES. All taxes and assessments due and payable by the Company have been paid or are
being contested in good faith by appropriate proceedings and the Company has filed all tax returns
which it is required to file.

     4.10 FINANCIAL STATEMENTS. The financial statements of Company heretofore delivered to the
Guarantor have been prepared in accordance with GAAP applied on a consistent basis throughout the
period involved and fairly present the Company’s financial condition as of the date or dates
thereof, and there has been no material adverse change in Company’s financial condition or
operations since the date of the financial statements. All factual information furnished by the
Company to the Guarantor in connection with this Agreement is and will be accurate on the date as
of which such information is delivered to the Guarantor.

     4.11 ENVIRONMENTAL. The conduct of the Company’s business operations and the condition of the
Company’s property does not and will not violate any federal laws, rules or ordinances for
environmental protection, regulations of the Environmental Protection Agency, any applicable local
or state law, rule, regulation or rule of common law or any judicial interpretation thereof
relating primarily to the environment or Hazardous Materials (as defined in the Loan Agreement).

     4.12 AFFIRMATIVE COVENANTS. Until full payment and performance of all obligations of the
Company to the Guarantor hereunder, the Company will, unless Guarantor consents otherwise in
writing:

          (a) Existence and Compliance. Maintain its existence, good standing and qualification to do
business, where required, and comply with all laws, regulations and governmental requirements
including, without limitation, environmental laws applicable to it or to any of its property,
business operations and transactions.

          (b) Adverse Conditions or Events. Promptly advise the Guarantor orally or in writing of (i)
any condition, event or act which comes to its attention that would or might materially adversely
affect the Guarantor’s rights under this Agreement or the Warrant, and (ii) any litigation in
excess of $500,000 is filed by or against Company, or (iii) any event that has occurred that would
constitute an event of default under the Loan Agreement.

          (c) Taxes and Other Obligations. Pay all of its taxes, assessments and other obligations,
including, but not limited to, taxes, costs or other expenses arising out of this transaction, as
the same become due and payable, except to the extent the same are being contested in good faith by
appropriate proceedings in a diligent manner.

     4.13 NEGATIVE COVENANTS. Until full payment and performance of all obligations of the Company
to the Guarantor hereunder, the Company will not, unless the Guarantor consents otherwise in
writing:

               (a) Character of Business. Change the general character of business as conducted at the date
hereof, or engage in any type of business not reasonably related to its business as presently
conducted.

5

 

EXECUTION COPY

               (b) Incur Obligations. Incur any obligations or take any action that could reasonably be
expected to, or have the effect of, causing the Company not to satisfy its obligations under
Section 8 of this Agreement.

5. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE GUARANTOR.

     The Guarantor hereby represents and warrants to the Company and agrees as follows:

     5.1 RELIANCE. The Guarantor understands that the Company has relied on the information and
representations with respect to the Guarantor set forth in this Section 5 in determining, among
other things, whether an investment in the Warrant is suitable for the Guarantor, and the Guarantor
represents and warrants that all such information is true and correct as of the date hereof.

     5.2 POWER AND AUTHORITY. The Guarantor has all requisite power and authority to execute and
deliver this Agreement and the Guarantee Documents and to carry out and perform its obligations
hereunder and thereunder.

     5.3 EXPERIENCE. The Guarantor is an “accredited investor” within the meaning of Regulation D
under the Securities Act and such Guarantor has no ability to acquire the Warrant Shares until at
least one year after the date the Warrants are issued.

     5.4. INFORMATION AND SOPHISTICATION. The Guarantor has received all the information it has
requested from the Company that it considers necessary or appropriate for deciding whether to
acquire the Warrant. The Guarantor has had an opportunity to ask questions and receive answers from
the Company regarding the terms and conditions of the Warrant and to obtain any additional
information necessary to verify the accuracy of the information given to the Guarantor. The
Guarantor further represents that it has such knowledge and experience in financial and business
matters that it is capable of evaluating the merits and risk of the investment in the Warrant and
the Warrant Shares (collectively, the “Securities”).

     5.5 DUE DILIGENCE. The Guarantor has consulted with its own legal, regulatory, tax, business,
investment, financial and accounting advisers in connection with its determination to enter into
this Agreement. The Guarantor has made its own decisions based upon its own judgment, due
diligence and advice from such advisers as it has deemed necessary and, except for the
representations and warranties expressly set forth herein, is not relying upon any information,
representation or warranty by the Company or any agent of the Company in determining to enter into
this Agreement.

     5.6. ABILITY TO BEAR ECONOMIC RISK. The Guarantor acknowledges that investment in the
Securities involves a high degree of risk. The Guarantor is able, without materially impairing its
financial condition, to hold the Securities for an indefinite period of time and to suffer a
complete loss of its investment. Neither the Securities and Exchange Commission nor any state
securities commission has approved any of the Securities or passed upon or endorsed the merits of
the offering of the Securities by the Company.

     5.7 LOCK-UP AGREEMENT. The Guarantor hereby agrees that, during the period of duration (not
to exceed one hundred eighty (180) days) specified by the Company and an underwriter of Common
Stock or other securities of the Company in an agreement in connection with any initial public
offering of the Company’s securities, following the effective date of the registration statement
for a public offering of the Company’s securities filed under the Securities Act, it shall not, to
the extent requested by the Company and such underwriter, directly or indirectly sell, offer to
sell, contract to sell (including, without limitation, any short sale), grant any option to
purchase or otherwise transfer or dispose of (other

6

 

EXECUTION COPY

than to donees who agree to be similarly bound) any securities of the Company held by it at any
time during such period, except Common Stock, if any, included in such registration.

     5.8 The Guarantor hereby acknowledges that:

IN THE EVENT THAT SALES OF THE SECURITIES OFFERED HEREBY ARE MADE TO FIVE (5) OR
MORE PERSONS IN FLORIDA, ALL PURCHASERS IN FLORIDA HAVE THE RIGHT TO VOID THE SALE
OF THE SECURITIES OFFERED HEREBY WITHIN THREE (3) DAYS AFTER THE PAYMENT OF THE
PURCHASE PRICE IS MADE TO THE COMPANY, AN AGENT OF THE COMPANY, OR AN ESCROW
AGENT, OR WITHIN THREE (3) DAYS AFTER THE AVAILABILITY OF THAT PRIVILEGE IS
COMMUNICATED TO SUCH PURCHASER, WHICHEVER OCCURS LATER. PAYMENTS FOR TERMINATED
SUBSCRIPTIONS VOIDED BY PURCHASERS AS PROVIDED FOR IN THIS PARAGRAPH WILL BE
PROMPTLY REFUNDED WITHOUT INTEREST.

     5.9 The Guarantor shall, at all times from the date hereof until the date the Company
effectuates a Loan Satisfaction, maintain, as security for the Loan, Eligible Collateral (as
defined in that certain Pledge Agreement dated of even date herewith between the Guarantor and the
Bank (the “Pledge Agreement”)) with an Adjusted Collateral Value (as defined in the Pledge
Agreement) in excess of the Guaranty Minimum (as defined in the Pledge Agreement).

6. REIMBURSEMENT OF PAYMENTS IN CONNECTION WITH GUARANTEE DOCUMENTS.

     (a) The Company hereby agrees to pay to the Guarantor (i) all reasonable and documented costs
and expenses (including court costs and reasonable legal expenses) incurred or expended by the
Guarantor in connection with (x) the Guarantor’s negotiation, drafting and execution of this
Agreement, the Guarantee Documents and any agreements with Magellan Group Investments, LLC, the
Guarantor’s review of all documents in connection with the Loan and the Guarantor’s establishment
of the Collateral Account (the “Initial Expenses”) and (y) the Bank’s taking any action
against the Guarantor to enforce the Bank’s rights under the Guarantee Documents (together with the
Initial Expenses, the “Expenses”) and (ii) to repay to Guarantor the Guarantor Payments.
Notwithstanding the foregoing or anything else to the contrary in this Agreement, the Company shall
not be required to reimburse the Guarantor for Expenses that the Guarantor would not have incurred
but for the Guarantor’s failure to satisfy the terms and conditions of this Agreement or the
Guarantee Documents.

     (b) Each payment to be made by the Company hereunder shall be due within thirty (30) days of
the receipt by the Company of a request for reimbursement from Guarantor; provided,
however, that if the date of any reimbursement request occurs prior to the Trigger Date, such
payment shall be made within thirty (30) days after the Trigger Date or on the same date the
Company is required to pay the Guarantee Fee in accordance with Section 1.2(c) hereof, whichever
occurs first. Notwithstanding the foregoing, the Company shall reimburse the Guarantor for the
Initial Expenses within ten (10) business days of the Closing.

     (c) All payments payable by the Company hereunder shall be made in immediately available funds
to an account that the Guarantor shall designate from time to time in writing to the Company.
Except for any Collection Expenses (which shall not bear any interest), payments due shall be made
with interest thereon from the due date (or, in the case of the Guarantor Payments, from the date
that the Guarantor made such payment) until payment thereof by the Company, at the Prime Rate
offered by the

7

 

EXECUTION COPY

Bank, plus 5%, and in effect as such due date. For the avoidance of doubt, the due date for
any reimbursement request shall be thirty (30) days after the date of a written reimbursement
request made by the Guarantor.

     (d) The Company shall make the payments specified above even if there is a dispute about
whether the Bank is or was entitled to take any action to enforce its rights under the Guarantee
Documents. In no event shall the Company be liable to Guarantor for any special, indirect or
consequential damages incurred by Guarantor.

7. DEFAULT; REMEDIES UPON DEFAULT.

     7.1 GUARANTOR DEFAULT.

          (a) The failure by the Guarantor to: (x) pay any Guarantor Payment (whether in cash or by the
Bank drawing on, taking control of or foreclosing the assets deposited into the Collateral Account)
which failure is not cured within two (2) business days of the Guarantor’s receipt of written
notice from the Company of such failure or (y) comply with the covenant set forth in Section 5.9
hereto shall constitute a “Key Default” hereunder.

          (b) Upon any Key Default by the Guarantor, the following shall occur immediately and
automatically, provided that the Company shall provide Guarantor with written notice promptly upon
learning of any such default: (a) the Warrant shall be cancelled; (b) the Company’s obligations to
make payments to the Guarantor under Section 1.2(b) of this Agreement shall be terminated; and (c)
the Company’s obligations under Section 6 to reimburse the Guarantor for Expenses shall be
terminated.

          (c) Notwithstanding anything to the contrary in this Agreement, the Guarantor shall indemnify,
defend and hold the Company harmless from and against all losses (including, without limitation,
reasonable attorneys fees and court costs) incurred by the Company as a result of the Guarantor’s
breach of any of its material obligations under this Agreement, including, but not limited to, a
breach that results in a Key Default; provided, however, (z) in no event shall the
Guarantor be liable to the Company for (A) any special, indirect or consequential damages; or (B)
an amount in excess of $1.3 million (the “Damages Cap”); provided, however,that if the Bank
liquidates all or any portion of the Collateral Account, the amount liquidated by the Bank shall
reduce the Damages Cap on a dollar for dollar basis.

     7.2 COMPANY DEFAULT. The failure by the Company to pay or perform any material obligation
hereunder (including, without limitation, a breach of its obligations under Section 8 below) which
failure is not cured within two (2) business days of the Company’s receipt of written notice from
the Guarantor of such failure shall constitute a default hereunder. Upon any such default by the
Company, the Guarantor’s obligations to pay the Guarantor Payments shall be terminated.
Notwithstanding anything to the contrary in this Agreement, the Company shall indemnify, defend and
hold the Guarantor harmless from and against all losses (including, without limitation, reasonable
attorneys fees and court costs) incurred by the Guarantor as a result of the Company’s failure to
comply with its obligations hereunder; provided that Company’s maximum liability to the Guarantor
under this Agreement shall not exceed $1.3 million.

8. REPAYMENT ELECTION.

     (a) Subject to this Section 8, in the event the Company does not close an initial public
offering of the Company’s Common Stock generating at least $30 million of net proceeds to the
Company by August 13, 2007, the Guarantor, by providing written notice to the Company (the

8

 

EXECUTION COPY

“Repayment Election Notice”) at any time between August 13, 2007 and October 15, 2007,
may compel the Company to effectuate (i) a BlueCrest Loan Satisfaction or (ii) a BlueCrest Loan
Satisfaction and a Loan Satisfaction. Within two (2) days of the Company’s receipt of the
Repayment Election Notice, the Company shall (x) provide notice (the “Other Guarantor
Notice”) to Mr. Bruce Carson, the R&A Spencer Family Limited Partnership, Dr. William Murphy
and Magellan Group Investments, LLC (collectively, the “Other Guarantors”) of the Company’s
receipt of the Repayment Election Notice and (y) (A) enter into the Requisite Substitution
Agreements (as defined below) or (B) effectuate a BlueCrest Loan Satisfaction or a BlueCrest Loan
Satisfaction and Loan Satisfaction (as specified in the Repayment Election Notice).

     (b) In anticipation of its receipt of a Repayment Election Notice, the Company may seek to,
but is not required to, locate Eligible Substitute Guarantors (as defined below) desiring to
provide collateral to secure the Loan in substitution of the Pledge and the Personal Guaranty. For
purposes of this Agreement, an “Eligible Substitute Guarantor” is a natural person or
entity that:

          (i) is an “Accredited Investor”;

          (ii) is acceptable to the Bank, in the Bank’s sole discretion;

          (iii) agrees to provide collateral to secure the Loan, which collateral is acceptable to the
Bank in the Bank’s sole discretion (“Substitute Collateral”);

          (iv) agrees to enter into a subordination agreement with BlueCrest Capital Finance, L.P.,
which subordination agreement is acceptable to BlueCrest Capital Finance, L.P. in its sole
discretion;

          (v) agrees to enter into a loan guarantee, payment and security agreement with the Company on
terms and conditions acceptable to the Company (“Substitute Loan Guarantee Agreements”);
and

          (vi) agrees to be bound by that certain Indemnification Agreement, dated as of the date
hereof, by and among the Guarantor and the Other Guarantors.

     (c) In the event that, within two (2) days of the date of the Company’s receipt of the
Repayment Election Notice (the “Substitution Period”), (i) the Company enters into fully
executed Substitute Loan Guarantee Agreements with one or more Eligible Substitute Guarantors
agreeing to provide Substitute Collateral in an amount equal to or greater than $1,100,000 (the
“Requisite Substitution Agreements”) and (ii) the Bank cancels the Pledge and the Personal
Guaranty, then the Company shall have no obligation to effectuate a BlueCrest Loan Satisfaction or
a BlueCrest Loan Satisfaction and Loan Satisfaction, as applicable, in accordance with Section
8(a).

     (d) In the event that the Company does not, within the Substitution Period, enter into the
Requisite Substitution Agreements and the Bank has not cancelled the Pledge and the Personal
Guaranty, the Company shall effectuate a BlueCrest Loan Satisfaction or a BlueCrest Loan
Satisfaction and Loan Satisfaction (as specified in the Repayment Election Notice) by the end of
the Substitution Period.

     (e) In the event that, in accordance with the Repayment Election Notice, (i) the Company
effectuates a BlueCrest Loan Satisfaction but not a Loan Satisfaction, (ii) the Company enters into
the Requisite Substitution Agreements and (iii) the Bank cancels the Pledge and the Personal
Guaranty:

          (i) the amount of the Guarantee Fee payable by the Company under this Agreement

9

 

EXECUTION COPY

shall be determined by multiplying the Collateral Amount by 5.0% and multiplying the resulting
amount by a fraction, the numerator of which is the number of days elapsed between the date hereof
and the date the Pledge and Personal Guaranty is cancelled by the Bank, and the denominator of
which is 365; and

          (ii) the Guarantor shall have no obligation to make any Guarantor Payments due after the end
of the Substitution Period.

     (f) Notwithstanding anything contained in this Agreement to the contrary, the
Company acknowledges and agrees that (i) the Company’s obligations under this Section 8 are a
material inducement for Guarantor to enter into this Agreement and provide the Bank with the Pledge
and the Personal Guaranty and but for the Company’s agreements under this Section 8, Guarantor
would not have entered into this Agreement or provided the Bank with the Pledge and the Personal
Guaranty; and (ii) that irreparable damage would occur to Guarantors in the event the provisions of
this Section 8 are not performed in accordance with their specific terms by the Company or are
otherwise breached by the Company. Accordingly, it is agreed that Guarantor shall be entitled to
an injunction or injunctions to prevent breaches of the provisions of this Section 8 and to enforce
specifically the terms and provisions hereof in any court of competent jurisdiction in the United
States or any state thereof, in addition to any other remedy to which they may be entitled at law
or equity.

     (g) In the event that, during the period commencing on the Effective Date and ending on August
13, 2007, the Company closes an initial public offering of the Company’s Common Stock generating at
least $30 million of net proceeds to the Company, the Company shall effectuate a Loan Satisfaction
within five (5) business days of the closing of such offering.

9. MISCELLANEOUS.

     9.1. BINDING AGREEMENT; NON-ASSIGNMENT. This Agreement shall inure to the benefit of and be
binding upon the parties hereto and their respective successors. This Agreement is not assignable
without the express written consent of both parties, which consent may be withheld for any reason.
Nothing in this Agreement, express or implied, is intended to confer upon any third party any
rights, remedies, obligations, or liabilities under or by reason of this Agreement except as
expressly otherwise provided in this Agreement. If the Guarantor secures the consent of a third
party to indemnify it for certain costs and expenses it may incur hereunder or in connection with
the Guaranty Documents, the Guarantor agrees that is shall provide the Company notice of such
agreement, including the contact information of the subject third party.

     9.2. GOVERNING LAW. This Agreement shall be governed by and construed under the laws of the
State of Florida, irrespective of any contrary result otherwise required under the conflict or
choice of law rules of Florida.

     9.3. COUNTERPARTS. This Agreement may be executed in counterparts, each of which shall be
deemed an original, but both of which together shall constitute one and the same instrument.

     9.4. TITLES AND SUBTITLES. The titles and subtitles used in this Agreement are used for
convenience only and are not to be considered in construing or interpreting this Agreement.

     9.5. NOTICES. Any notice required or permitted under this Agreement must be given in writing
and shall be deemed effectively given upon personal delivery or upon overnight mail, postage
prepaid, if to the Company, addressed to William H. Kline, Chief Financial Officer, Bioheart, Inc.
13794 NW 4th Street, Suite 212, Sunrise, Florida 33325, with a copy to David E. Wells,
Esq., Hunton & Williams, LLP, 1111 Brickell Avenue, Suite 2500, Miami, Florida 33131, or to the
Guarantor at

10

 

EXECUTION COPY

Mr. Howard J. Leonhardt, [insert address], with a copy to Tobin & Reyes, P. A., Attn: David S. Tobin,
The Plaza, 5355 Town Center Road, Suite 204, Boca Raton, FL 33486 and Mrs. Brenda Leonhardt,
[insert address] with a copy to Sherman Law Offices, Attn: Craig B. Sherman, 1000 Corporate Drive,
Suite 310, Fort Lauderdale, Florida 33334 or at such other address as a party may designate by ten
days’ advance written notice to the other party.

     9.6. MODIFICATION; WAIVER. No modification or waiver of any provision of this Agreement or
consent to departure therefrom shall be effective unless in writing and approved by the Company and
the Guarantor.

     9.7. FURTHER ASSURANCES. The parties shall take such further actions, and execute, deliver and
file such documents, as may be necessary or appropriate to effectuate the intent of this Agreement.

     9.8. CONSTRUCTION. The language used in this Agreement shall be deemed to be the language
chosen by the parties to express their mutual intent, and no rule of strict construction shall be
applied against any party. Any references to any federal, state, local or foreign statute or law
shall also refer to all rules and regulations promulgated thereunder, unless the context otherwise
requires. Unless the context otherwise requires: (a) a term has the meaning assigned to it by this
Agreement; (b) forms of the word “include” mean that the inclusion is not limited to the items
listed; (c) “or” is disjunctive but not exclusive; (d) words in the singular include the plural,
and in the plural include the singular; (e) provisions apply to successive events and transactions;
(f) “hereof”, “hereunder”, “herein” and “hereto” refer to the entire Agreement and not any section
or subsection; and (g) “$” means the currency of the United States.

     9.9. ENTIRE AGREEMENT. This Agreement and the Exhibits hereto constitute the full and entire
understanding and agreement between the parties with regard to the subjects hereof and no party
will be liable or bound to the other in any manner by any representations, warranties, covenants
and agreements other than those specifically set forth herein.

     9.10 VENUE. The parties irrevocably submit to the exclusive jurisdiction of the courts of
State of Florida located in Broward County and federal courts of the United States for the Southern
District of Florida in respect of the interpretation and of the provisions of this Agreement and in
respect of the transactions contemplated hereby.

     9.11 SPECIFIC PERFORMANCE. The parties hereto acknowledge and agree that irreparable damage
would occur in the event that any of the provisions of this Agreement were not performed in
accordance with their specific terms or were otherwise breached. Accordingly, it is agreed that
they shall be entitled to an injunction or injunctions to prevent breaches of the provisions of
this Agreement and to enforce specifically the terms and provisions hereof in any court of
competent jurisdiction in the United States or any state thereof, in addition to any other remedy
to which they may be entitled at law or equity.

     9.12 ATTORNEYS’ FEES. In the event of any litigation, including appeals, with regard to this
Agreement, the prevailing party shall be entitled to recover from the non-prevailing party all
reasonable fees, costs, and expenses of counsel (at pre-trial, trial and appellate levels).

11

 

EXECUTION COPY

     IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above.

	 	 	 	 	 	 	 
	 	 	BIOHEART, INC.
	 
	 	 	 	 	 	 
	 

	 	BY:	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	Name:	 	 	 	 
	 

	 	Title:	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 	 	 
	 	 	Howard Leonhardt
	 
	 	 	 	 	 	 
	 	 	 	 	 
	 	 	Brenda Leonhardt

12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00124-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00124-of-00352.parquet"}]]